Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752464 | 0.79 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4668184 | 0.79 | SLC28A1 (0.50) | P2RY2 | |
| SCHEMBL2512324 | 0.76 | LMNA (0.51) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3474450 | 0.76 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18740734 | 0.76 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL3345914 | 0.75 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL383275 | 0.75 | LMNA (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11430667 | 0.75 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11796922 | 0.75 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5150771 | 0.73 | NT5E (0.51) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365755-B1 | USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES | PHARMA NORD APS (DK) | 2008-10-22 | — | — | EP | disclosed |
| US-6992072-B2 | Combating side-effects | PHARMA NORD APS (DK) | 2006-01-31 | — | — | US | disclosed |
| US-20040138157-A1 | Combating side-effects | PHARMA NORD APS (DK) | 2004-07-15 | — | — | US | disclosed |
| EP-1365755-A2 | USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES | Walker, Ulrich (DE) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002069943-A2 | USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES | WALKER ULRICH (DE) | 2002-09-12 | — | — | WO | disclosed |
| EP-0716603-A4 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | UAB RESEARCH FOUNDATION (US) | 2000-10-04 | — | — | EP | disclosed |
| US-5723449-A | ANTISECRETORY AGENTS AND ANTICARCINOGENIC AGENTS | THE UAB RESEARCH FOUNDATION (US) | 1998-03-03 | — | — | US | disclosed |
| US-5567689-A | CONCURRENT ADMINISTERING MIXTURE OF URIDINE PHOSPHORYLASE INHIBITOR, URIDINE SECRETION INHIBITOR AND(OR) COMPOUNDWHICH COMPETES WITH URIDINE IN RENAL TRANSPORTATION MECHANISM | THE UAB RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0716603-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995005180-A1 | METHODS AND COMPOSITIONS FOR INHIBITING URIDINE SECRETION | THE UAB RESEARCH FOUNDATION (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138157-A1 | Combating side-effects | POLRMT, TK2, POLM | LMNA 1911/4885THRB 4004/4885MTOR 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.